ClinicalTrials.gg
RecruitingNCT07104565Updated Oct 30, 2026

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

A Phase 2 interventional study of INCA000585 in Immune Thrombocytopenia, sponsored by Incyte Corporation. Recruiting at 39 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 30, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States — 18 open to participants now, 22 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United States.

Planned enrollment
41st of 94
56 · median 42
Started
2025
with 11 others
Phase 2
32 of 110
3 open now
Primary completion
2027-09
later than 9 of 21 live
Registered
104th of 110
by date

Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, this one is the 41st largest by planned enrollment of the 94 interventional ones that give a count, is one of 12 that started in 2025, is one of 32 in phase 2, reaches primary completion later than 9 of the 21 other live ones, and was the 104th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

18 of the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.

03

Conditions studied

  • Immune Thrombocytopenia

Keywords

  • primary warm autoimmune hemolytic anemia
  • primary immune thrombocytopenia
  • anti-CD19 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Ability to comprehend and willingness to sign a written ICF for the study.

  • Aged ≥ 18 years.
  • Confirmed historical diagnosis of one of the following blood disorders:

    • Primary ITP.
    • Primary wAIHA.
  • No history of splenectomy.
  • Confirmed transient response to at least 1 prior early-line treatment (eg, , IVIG, rituximab):

    • Primary ITP: Increase in count to ≥ 30 × 109/L with at least a 2-fold increase of baseline platelet count.
    • Primary wAIHA: Increase in to ≥ 10 g/dL with an increase of at least 2 g/dL from baseline.
  • Received ≥ 1 standard course of rituximab (375 mg/kg × 4 weekly doses or 2 doses of 1000 mg flat dose every 2 weeks) with last dose given at least 6 months prior to initiation of study treatment. Note: If rituximab was the only prior therapy, individuals with NR to rituximab will not be eligible.

    • Primary ITP: a PR (platelet count ≥ 30 × 109/L with at least a 2-fold increase of baseline platelet count) within 6 months of the last administered dose followed by relapse OR a CR (platelet count > 100 × 109/L) lasting \< 48 weeks OR NR (platelet count \< 30 × 109/L or less than 2-fold increase of baseline platelet count or bleeding) within 6 months of the last administered dose.
    • Primary wAIHA: a PR with hemoglobin ≥ 10 g/dL and with an increase of at least 2 g/dL from baseline OR a CR (hemoglobin ≥ 12 g/dL and normalization of hemolytic markers) OR NR (hemoglobin \< 10 g/dL or \< 2 g/dL increase of baseline hemoglobin).
  • Persistent or chronic active primary ITP or active primary wAIHA with indication for treatment at the time of inclusion.

    • Primary ITP: platelet count \< 30 × 109/L within the 15 days before treatment is scheduled to begin (Day 1).

Note: Participants treated with a rescue therapy during screening in response to a documented platelet count \< 30 × 109/L are eligible, irrespective of platelet count within 15 days of Day 1.

  • Primary wAIHA: hemoglobin \< 10 g/dL documented with DAT result positive for IgG, with or without C3d, and evidence of hemolysis based on low haptoglobin, elevated LDH, and/or indirect .
  • performance status of 0 to 2.
  • Willingness to avoid pregnancy or fathering children.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Clinical manifestations typical for cold agglutinin disease.
  • Life-threatening bleeding or urgent need to elevate the count for primary ITP or hemodynamic instability or \< 6 g/dL with urgent need to elevate hemoglobin for primary wAIHA within 2 weeks prior to Day 1.
  • Prior treatment with anti-CD19 therapy (eg, mAb, bispecific T-cell engager, or CAR T cell) for any indication.
  • Previous severe allergic reaction to a mAb or known allergy to any component/ of tafasitamab.
  • Changes in doses (> 10%) of permitted disease-related therapies, including oral and TPO-RA (primary ITP participants) within 2 weeks prior to Day 1, or change in ESA (primary wAIHA participants) dose within 2 weeks prior to Day 1.
  • Evidence of hypogammaglobulinemia during screening (IgA \< 70 mg/dL, IgG \< 700 mg/dL, and/or IgM \< 40 mg/dL) and frequent and/or severe infections.
  • Women who are pregnant or breastfeeding.
  • History of except for the following:

    • Malignancy treated with curative intent with no evidence of active disease for more than 2 years before screening.
    • Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanoma skin cancer.
    • Adequately treated carcinoma in situ without current evidence of disease.
  • Congestive heart failure ( of \< 50%, assessed by 2 dimensional echocardiography or a multigated acquisition scan).
  • Participants with:

    • Known positive test result for (with HCV antibody serology testing) and a positive test for HCV RNA.

Note: Participants with positive serology must have been tested for HCV RNA and are eligible only in the case of negative HCV RNA test result.

  • Known positive test result for chronic infection (defined by HBsAg positivity or positive HBV DNA test result).

Note: Participants with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA was undetectable, provided that they are willing to undergo monthly ongoing DNA testing. Antiviral prophylaxis may be administered as per institutional guidelines.

Note: Participants who have protective titers of HBsAb (HBsAb positive, HBcAb negative, and HBsAg negative) after vaccination or prior HBV infection are eligible.

  • Seropositivity for or history of active viral infection with .
  • Active systemic infection (including infection with SARS-CoV-2).
  • Participants in a severely state, per investigator's clinical assessment.
  • Receipt of a within 4 weeks prior to the first infusion of tafasitamab (inactivated and killed vaccines are acceptable).
  • Coagulation or platelet function abnormality.
  • An active medical condition with a strong indication for treatment with anticoagulation agents (eg, intracoronary stent within 12 months).
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Toxicities related to prior therapies must be (v5.0) ≤ Grade 1 at the time of study treatment/enrollment (except for chronic toxicities [≤ Grade 2] not expected to resolve).
  • Chronic infectious disease requiring systemic antibiotics or antifungal or antiviral medications.
  • Unwillingness to undergo transfusion with blood components.
  • Current use of prohibited medication as described in the protocol.
  • Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - primary immune thrombocytopenia (ITP)

    INCA000585 will be administered intravenously.

    Drug: INCA000585

  • Experimental
    Cohort 2 - primary warm autoimmune hemolytic anemia (wAIHA)

    INCA000585 will be administered intravenously.

    Drug: INCA000585

Interventions

  • DrugINCA000585

    Tafasitamab will be administered intravenously at protocol defined timepoints.

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as any adverse event, either reported for the first time or worsening of a pre-existing event after the first dose of study drug up to 90 days after the last dose of study drug.

    Time frame: Up to 52 weeks

  2. Stable platelet response

    Defined as platelet count ≥ 50 × 109/L in the absence of clinically significant bleeding or rescue therapy at ≥ 2 consecutive assessments any time after Day 56 until Week 48 in participants with primary ITP.

    Time frame: After Day 56 up to Week 48

  3. Stable hemoglobin response

    Defined as hemoglobin ≥ 10 g/dL and a ≥ 2 g/dL increase from baseline in the absence of rescue therapy at ≥ 2 consecutive assessments any time after Day 56 until Week 48 in participants with primary wAIHA.

    Time frame: After Day 56 up to Week 48

Secondary outcomes

  1. Complete Response (CR)

    Defined as platelet count ≥ 100 × 109/L at Week 24 in the absence of clinically significant bleeding or rescue therapy in participants with primary ITP.

    Time frame: Week 24

  2. CR (complete remission)

    Defined as platelet count ≥ 100 × 109/L at Week 48 in the absence of clinically significant bleeding or rescue therapy in participants with primary ITP.

    Time frame: Week 48

  3. Partial Response (PR)

    Defined as platelet count ≥ 30 × 109/L and at least a 2-fold increase of baseline platelet count at Week 24 in the absence of clinically significant bleeding or rescue therapy in participants with primary ITP.

    Time frame: Week 24

  4. Duration of stable platelet response

    Defined as time from start of stable platelet response to loss of platelet response (\< 50 × 109/L), clinically significant bleeding, need for rescue therapy, or death, whichever occurs first in participants with primary ITP.

    Time frame: Up to Week 48

  5. Duration of CR

    Defined as time from the start of CR to loss of CR (platelet count \< 100 × 109/L), clinically significant bleeding, need for rescue therapy, or death, whichever occurs first in participants with primary ITP.

    Time frame: Up to Week 48

  6. Duration of response

    Defined as time from the date of the first response (PR or CR) to the loss of response (platelet count \< 30 × 109/L or a less than a 2-fold increase of baseline platelet count), clinically significant bleeding, need for rescue therapy, or death, whichever occurs first in participants with primary ITP.

    Time frame: Up to Week 48

  7. CR

    Defined as hemoglobin ≥ 12 g/dL and normalization of hemolytic markers (unconjugated bilirubin, LDH, haptoglobin, and reticulocytes) at Week 24 in the absence of rescue therapy in participants with primary wAIHA.

    Time frame: Week 24

  8. CR (Complete remission)

    Defined as hemoglobin ≥ 12 g/dL and normalization of hemolytic markers (unconjugated bilirubin, LDH, haptoglobin, and reticulocytes) at Week 48 in the absence of rescue therapy in participants with primary wAIHA.

    Time frame: Week 48

  9. PR

    Defined as hemoglobin ≥ 10 g/dL and a ≥ 2 g/dL increase from baseline at Week 24 in the absence of rescue therapy in participants with primary wAIHA.

    Time frame: Week 24

  10. Duration of stable hemoglobin response

    Defined as time from start of stable hemoglobin response to loss of stable hemoglobin response (\< 10 g/dL or a \< 2 g/dL increase from baseline), need for rescue therapy, or death, whichever occurs first in participants with primary wAIHA.

    Time frame: Up to Week 48

  11. Duration of CR

    Defined as time from start of CR to loss of CR (hemoglobin \< 12 g/dL or abnormal hemolytic markers \[unconjugated bilirubin, LDH, haptoglobin, and reticulocytes\]), need for rescue therapy, or death, whichever occurs first in participants with primary wAIHA.

    Time frame: Up to Week 48

  12. Duration of response

    Defined as time from the date of the first response (PR or CR) to the loss of response (hemoglobin \< 10 g/dL), need for rescue therapy, or death, whichever occurs first in participants with primary wAIHA.

    Time frame: Up to Week 48

  13. Serum concentrations of tafasitamab

    Serum concentrations of tafasitamab at each assessed timepoint.

    Time frame: Up to Week 48

  14. Change from baseline in serum antidrug antibody levels

    Time frame: Up to Week 48

07

Study locations

39 of 39 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 20 months after the start.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 5, 2025
StartActual
Dec 29, 2025
Primary completionEst.
Sep 23, 2027
CompletionEst.
Mar 9, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Fred Hutchinson Cancer Center is now Recruiting
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Fred Hutchinson Cancer Center is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07104565
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Dec 29, 2025
Primary completion
Sep 23, 2027 (estimated)
Completion
Mar 9, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion